Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Alpine Immune Sciences Inc (ALPN)

Alpine Immune Sciences Inc (ALPN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 68,311
  • Shares Outstanding, K 18,588
  • Annual Sales, $ 710 K
  • Annual Income, $ -36,490 K
  • 60-Month Beta 1.78
  • Price/Sales 97.03
  • Price/Cash Flow N/A
  • Price/Book 1.96

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.55
  • Number of Estimates 3
  • High Estimate -0.36
  • Low Estimate -0.67
  • Prior Year -0.80
  • Growth Rate Est. (year over year) +31.25%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.33 +57.73%
on 11/15/19
3.95 -6.96%
on 12/11/19
+1.17 (+47.00%)
since 11/13/19
3-Month
2.25 +63.33%
on 11/13/19
4.62 -20.45%
on 09/23/19
-0.16 (-4.30%)
since 09/13/19
52-Week
2.25 +63.33%
on 11/13/19
8.24 -55.42%
on 04/10/19
-1.14 (-23.68%)
since 12/13/18

Most Recent Stories

More News
Alpine Immune Sciences Presents ALPN-101 Phase 1 Healthy Volunteer Study Data and Details of Upcoming Phase I/II BALANCE GVHD Study at the 61st American Society of Hematology Annual Meeting

--Human experience supports both IV and SQ dosing regimens

ALPN : 3.67 (-0.14%)
Alpine Immune Sciences to Participate in Fireside Chat at 31st Annual Piper Jaffray Healthcare Conference

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced...

ALPN : 3.67 (-0.14%)
Alpine Immune Sciences Provides Corporate Update and Reports Third Quarter 2019 Financial Results

--Phase 1 Study (NEON-1) of Lead Oncology Program ALPN-202 Planned to Commence in Q1 2020

ALPN : 3.67 (-0.14%)
Alpine Immune Sciences Presents New ALPN-101 Preclinical Data at the 2019 American College of Rheumatology (ACR) Annual Meeting

--Preclinical activity suggests unique effectiveness across a range of rheumatic and other inflammatory diseases

ALPN : 3.67 (-0.14%)
Alpine Immune Sciences Presents New Preclinical Data at The Society for Immunotherapy of Cancer's (SITC) 34th Annual Meeting

--ALPN-202 able to increase CD8+ T-cells in tumors

ALPN : 3.67 (-0.14%)
Alpine Immune Sciences Announces Oral Presentation of ALPN-101 at the 61st American Society of Hematology Annual Meeting and Exposition

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced...

ALPN : 3.67 (-0.14%)
Alpine Immune Sciences Completes Enrollment of Phase I Study of ALPN-101 and Announces Third Quarter Conference Call

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced that...

ALPN : 3.67 (-0.14%)
Alpine Immune Sciences Announces Upcoming Scientific Presentations at SITC and ACR/ARHP 2019 Annual Meetings

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced...

ALPN : 3.67 (-0.14%)
Alpine Immune Sciences to Present at 2019 Ladenburg Thalmann Healthcare Conference

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer, autoimmune/inflammatory, and other diseases, today announced...

ALPN : 3.67 (-0.14%)
Alpine Immune Sciences Provides Pipeline Update and Reports Second Quarter 2019 Financial Results

--ALPN-202 Submission for Clinical Trial Authorization Anticipated by Year End 2019

ALPN : 3.67 (-0.14%)
ADAP : 1.22 (-1.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Trade ALPN with:

Business Summary

Alpine Immune Sciences Inc. operates as a specialty pharmaceutical company. It engages in the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders and other diseases. Alpine Immune Sciences Inc., formerly known as Nivalis Therapeutics, is based...

See More

Key Turning Points

2nd Resistance Point 3.85
1st Resistance Point 3.76
Last Price 3.67
1st Support Level 3.54
2nd Support Level 3.41

See More

52-Week High 8.24
Fibonacci 61.8% 5.95
Fibonacci 50% 5.25
Fibonacci 38.2% 4.54
Last Price 3.67
52-Week Low 2.25

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar